Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Bertelli

Showing results (91-100 of 93) with videos related to

Pageof 10
Sort By:
You have reached the last page of results.This site can display upto 93 results.
Gynecologic Oncology|June 1, 2021
OVPSYCH2: A randomized controlled trial of psychological support versus standard of care following chemotherapy for ovarian cancerE Frangou, G Bertelli, S Love, et al.
Journal of Bone Oncology|December 29, 2018
Benefits and risks of adjuvant treatment with zoledronic acid in stage II/III breast cancer. 10 years follow-up of the AZURE randomized clinical trial (BIG 01/04)R E Coleman, M Collinson, W Gregory, et al.
Lancet (London, England)|February 20, 2007
Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trialR C Coombes, L S Kilburn, C F Snowdon, et al.
Pageof 10

Showing results (91-100 of 93) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 93 results.
Gynecologic Oncology|June 1, 2021
OVPSYCH2: A randomized controlled trial of psychological support versus standard of care following chemotherapy for ovarian cancerE Frangou, G Bertelli, S Love, et al.
Journal of Bone Oncology|December 29, 2018
Benefits and risks of adjuvant treatment with zoledronic acid in stage II/III breast cancer. 10 years follow-up of the AZURE randomized clinical trial (BIG 01/04)R E Coleman, M Collinson, W Gregory, et al.
Lancet (London, England)|February 20, 2007
Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trialR C Coombes, L S Kilburn, C F Snowdon, et al.
Pageof 10